Your browser doesn't support javascript.
loading
Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile.
Acevedo, Mónica L; Gaete-Argel, Aracelly; Alonso-Palomares, Luis; de Oca, Marco Montes; Bustamante, Andrés; Gaggero, Aldo; Paredes, Fabio; Cortes, Claudia P; Pantano, Sergio; Martínez-Valdebenito, Constanza; Angulo, Jenniffer; Le Corre, Nicole; Ferrés, Marcela; Navarrete, Marcelo A; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo.
Afiliação
  • Acevedo ML; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Gaete-Argel A; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Alonso-Palomares L; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • de Oca MM; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Bustamante A; Escuela de Medicina, Universidad de Magallanes, Punta Arenas, Chile.
  • Gaggero A; Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Paredes F; Laboratorio de Virología Ambiental, Programa de Virología, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Cortes CP; Departamento de Epidemiología, Ministerio de Salud de Chile, Santiago, Chile.
  • Pantano S; Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.
  • Martínez-Valdebenito C; Clínica Santa María, Santiago, Chile.
  • Angulo J; Departamento de Medicina Centro, Universidad de Chile, Santiago, Chile.
  • Le Corre N; Biomolecular Simulations Group, Instituto Pasteur de Montevideo, Montevideo, Uruguay.
  • Ferrés M; Departamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Navarrete MA; Laboratorio de Infectología y Virología Molecular, Laboratorio de Bioseguridad Nivel 3, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Valiente-Echeverría F; Departamento de Enfermedades Infecciosas e Inmunología Pediátricas, División de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Soto-Rifo R; Laboratorio de Infectología y Virología Molecular, Laboratorio de Bioseguridad Nivel 3, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Nat Microbiol ; 7(4): 524-529, 2022 04.
Article em En | MEDLINE | ID: mdl-35365787
SARS-CoV-2 variant Lambda was dominant in several South American countries, including Chile. To ascertain the efficacy of local vaccination efforts, we used pseudotyped viruses to characterize the neutralization capacity of antibodies elicited by CoronaVac (n = 53) and BNT162b2 (n = 56) in healthcare workers from Clínica Santa María and the Faculty of Medicine at Universidad de Chile, as well as in convalescent plasma from individuals infected during the first wave visiting the Hospital Clínico at Pontificia Universidad Católica (n = 30). We observed that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac, with differences ranging from 7.4-fold for the ancestral spike (Wuhan-Hu-1) to 8.2-fold for the Lambda spike and 13-fold for the Delta spike. Compared with the ancestral virus, neutralization against D614G, Alpha, Gamma, Lambda and Delta variants was reduced by between 0.93- and 4.22-fold for CoronaVac, 1.04- and 2.38-fold for BNT162b2, and 1.26- and 2.67-fold for convalescent plasma. Comparative analyses among the spike structures of the different variants suggest that mutations in the spike protein from the Lambda variant, including the 246-252 deletion in an antigenic supersite at the N-terminal domain loop and L452Q/F490S within the receptor-binding domain, may account for immune escape. Interestingly, analyses using pseudotyped and whole viruses showed increased entry rates into HEK293T-ACE2 cells, but reduced replication rates in Vero-E6 cells for the Lambda variant when compared with the Alpha, Gamma and Delta variants. Our data show that inactivated virus and messenger RNA vaccines elicit different levels of neutralizing antibodies with different potency to neutralize SARS-CoV-2 variants, including the variant of interest Lambda.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: America do sul / Chile Idioma: En Revista: Nat Microbiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Chile País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans País/Região como assunto: America do sul / Chile Idioma: En Revista: Nat Microbiol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Chile País de publicação: Reino Unido